RetMap, Inc is a medical device startup delivering products that reduce vision loss through earlier detection of progressive eye disease. Incorporated in 2009, the founders self-funded several years of R&D on a pipeline product (CLEAr Lens™); in 2017 we pivoted to our first-to-launch product (RM Electrode™), closing a pre-seed round in 2018 and launching the veterinary-use RM Electrode™ in 2019. FDA clearance and launch of the human-use RM Electrode™ is expected in Q2 2022.

We believe that early disease detection is the key to fighting blindness. Our goal is to maximize the useful vision of people with progressive eye diseases through more effective screening, more accurate diagnosis, and more informative monitoring during disease management. We achieve this by improving access to testing through products that provide greater comfort, safety, efficacy, and clinical throughput. We also improve the tests themselves, with patented technologies that gather more information abou...
RetMap, Inc is a medical device startup delivering products that reduce vision loss through earlier detection of progressive eye disease. Incorporated in 2009, the founders self-funded several years of R&D on a pipeline product (CLEAr Lens™); in 2017 we pivoted to our first-to-launch product (RM Electrode™), closing a pre-seed round in 2018 and launching the veterinary-use RM Electrode™ in 2019. FDA clearance and launch of the human-use RM Electrode™ is expected in Q2 2022.

We believe that early disease detection is the key to fighting blindness. Our goal is to maximize the useful vision of people with progressive eye diseases through more effective screening, more accurate diagnosis, and more informative monitoring during disease management. We achieve this by improving access to testing through products that provide greater comfort, safety, efficacy, and clinical throughput. We also improve the tests themselves, with patented technologies that gather more information about the eye and do it faster.

The Electroretinogram (ERG) is like an ECG for the eye. ERGs are obtained with the help of a sensor. ERG tests are currently very expensive to perform as clinics struggle with outdated ERG sensors (40+ year-old designs). There are two types of ERG sensors in the market today – reusable and single-use disposable. The reusable sensors are expensive to buy, have long lead times, need quarterly reconditioning, and require a rigorous, time consuming and expensive cleaning (due to accreditation requirements). They are banned in the EU and are being phased-out in most US clinics. The single-use sensor, due to its unstable design, results in highly variable responses, increased test times and non-reimbursed re-tests, increasing testing costs for clinics.

Our solution is a direct replacement for existing ERG sensors – the RM Electrode™. The RM Electrode™ is a plug-and-play single-use disposable sensor with high diagnostic power. Its key design features provide high stability, large responses and low noise. The sensor is designed to increase patient comfort and obtain ERG test results in a considerably shorter amount of time. Cleaner ERG responses, reduced repetitions and shorter test times reduce the overall cost of the ERG tests and improve the bottom-line in most clinics.
More information

Employees

David Vigil
Admin
David Vigil CEO I am a Fortune 100 senior executive with global experience. I have worked in both venture and private equity backed technology firm as CEO.
Michael Aceti
Admin
Michael Aceti
Shresta Patangay
Admin
Shresta Patangay